1. 1. The International Conference on Harmonization, ICH Q3A/B, “Impurities in New Drug Substances/New Drug Products”.
2. 2. US FDA, Guidance for Industry: Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches. Draft, December, 2008.
3. 3. EMA, Guideline on the limits of genotoxic impurities, CPMP/SWP/5199/02, EMEA/CHMP/QWP/251344/2006, 28 June, 2006.
4. 4. EMA, Questions and Answers on the Guideline on the limits of genotoxic impurities, EMEA/CHMP/SWP/431994/2007, 23 September, 2010.
5. 5. L. Müller, R. J. Mauthe, C. M. Riley, M. M. Andino, D. De Antonis, C. Beels, J. DeGeorge, A. G. M. De Knaep, D. Ellison, J. A. Fagerland, R. Frank, B. Fritschel, S. Galloway, E. Harpur, C. D. N. Humfrey, A. S. Jacks, N. Jagota, J. Mackinnon, G. Mohan, D. K. Ness, M. R. O’Donovan, M. D. Smith, G. Vudathala, and L. Yotti, Regul. Toxicol. Pharmacol., 2006, 44, 198.